Cited by Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review

Neurotransmitter systems in the etiology of major neurological disorders: Emerging insights and therapeutic implications DOI

Mallikarjuna Nimgampalle,

Harshini Chakravarthy, Sapana Sharma

et al.

Ageing Research Reviews, Journal Year: 2023, Volume and Issue: 89, P. 101994 - 101994

Published: June 28, 2023

Language: Английский

Citations

Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis DOI

Jiwon Oh, Douglas L. Arnold, Bruce Cree

et al.

New England Journal of Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton's tyrosine kinase inhibitor that modulates peripheral inflammation persistent immune activation within the central nervous system, including disease-associated microglia B cells. More data are needed on its efficacy safety in treating relapsing multiple sclerosis. In two phase 3, double-blind, double-dummy, event-driven trials (GEMINI 1 GEMINI 2), participants with sclerosis were randomly assigned a 1:1 ratio to receive tolebrutinib (60 mg once daily) or teriflunomide (14 daily), each matching placebo. The primary end point was annualized relapse rate. key secondary confirmed worsening of disability sustained for at least 6 months, which assessed time-to-event analysis pooled across trials. A total 974 enrolled 1, 899 2. median follow-up 139 weeks. rate groups 0.13 0.12, respectively, (rate ratio, 1.06; 95% confidence interval [CI], 0.81 1.39; P = 0.67) 0.11 0.11, 2 1.00; CI, 0.75 1.32; 0.98). percentage months 8.3% 11.3% (hazard 0.71; 0.53 0.95; no formal hypothesis testing conducted owing prespecified hierarchical plan, width not adjusted testing). who had adverse events similar treatment groups, although minor bleeding higher group than (petechiae occurred 4.5% vs. 0.3%, heavy menses 2.6% 1.0%). superior decreasing rates among (Funded by Sanofi; ClinicalTrials.gov numbers, NCT04410978 NCT04410991, respectively.).

Language: Английский

Citations

Sex and Gender Differences in Neurodegenerative Diseases: Challenges for Therapeutic Opportunities DOI

Annalisa Bianco,

Ylenia Antonacci, Maria Liguori

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(7), P. 6354 - 6354

Published: March 28, 2023

The term "neurodegenerative diseases" (NDs) identifies a group of heterogeneous diseases characterized by progressive loss selectively vulnerable populations neurons, which progressively deteriorates over time, leading to neuronal dysfunction. Protein aggregation and have been considered the most characteristic hallmarks NDs, but growing evidence confirms that significant dysregulation innate immune pathways plays crucial role as well. NDs vary from multiple sclerosis, in autoimmune inflammatory component is predominant, more "classical" such Parkinson's disease, Alzheimer's amyotrophic lateral spinal muscular atrophy. Of interest, many clinical differences reported seem be closely linked sex, may justified changes mechanisms between affected females males. In this review, we examined some studied looking at their pathogenic phenotypical features highlight sex-related discrepancies, if any, with particular interest individuals' responses treatment. We believe pointing out these practice help achieve successful precision personalized care.

Language: Английский

Citations

Dissecting the Relationship Between Neuropsychiatric and Neurodegenerative Disorders DOI

Rohan Gupta,

Dia Advani, Divya Yadav

et al.

Molecular Neurobiology, Journal Year: 2023, Volume and Issue: 60(11), P. 6476 - 6529

Published: July 17, 2023

Language: Английский

Citations

Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications DOI

Zuber Khan, Sidharth Mehan, Ghanshyam Das Gupta

et al.

Neuroscience, Journal Year: 2024, Volume and Issue: 548, P. 9 - 26

Published: April 30, 2024

Language: Английский

Citations

Serum biomarkers at disease onset for personalized therapy in multiple sclerosis DOI

Enric Monreal, José Ignacio Fernández-Velasco, Roberto Álvarez‐Lafuente

et al.

Brain, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 5, 2024

Abstract The potential for combining serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels to predict worsening disability in multiple sclerosis remains underexplored. We aimed investigate whether sNfL sGFAP values identify distinct subgroups of patients according the risk their response disease-modifying treatments (DMTs). This multicentre study, conducted across 13 European hospitals, spanned from 15 July 1994 18 August 2022, with follow-up until 26 September 2023. enrolled who had samples collected within 12 months disease onset before initiating DMTs. Multivariable regression models were used estimate relapse-associated (RAW), progression independent relapse activity (PIRA) Expanded Disability Status Scale (EDSS) score 3. Of 725 included, median age was 34.2 (interquartile range, 27.6–42.4) years, 509 (70.2%) female. duration 6.43 4.65–9.81) years. Higher associated an elevated RAW [hazard ratio (HR) 1.45; 95% confidence interval (CI) 1.19–1.76; P < 0.001], PIRA (HR 1.43; CI 1.13–1.81; = 0.003) reaching EDSS 3 1.55; 1.29–1.85; 0.001). Moreover, higher linked a achieving 1.36; 1.06–1.74; 0.02) and, low values, 1.86; 1.01–3.45; 0.04). also examined combined effect levels. Patients exhibited all outcomes served as reference. Untreated high showed RAW, Injectable or oral DMTs reduced these but failed mitigate Conversely, high-efficacy counteracted heightened outcomes, except increased 3, which remained unchanged either other In conclusion, evaluating at might phenotypes diverse immunological pathways acquisition therapeutic response.

Language: Английский

Citations

Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis DOI

Olaf Hoffmann, Friedemann Paul, Rocco Haase

et al.

Patient Preference and Adherence, Journal Year: 2024, Volume and Issue: Volume 18, P. 455 - 466

Published: Feb. 1, 2024

Background: To reduce the risk of long-term disability in people with Multiple Sclerosis (pwMS), an increasing number diseasemodifying immune therapies (DMT) are available, involving diverse mechanisms action, levels efficacy, treatment risks, and tolerability aspects.Including patient preferences expectations shared decision-making may improve satisfaction, adherence, persistence.Purpose: investigate alignment individual pwMS their actual DMT its effect on health-related quality life (HRQoL), discontinuation.Methods: A total 401 beginning a new were enrolled from 2015 to 2018 non-interventional study at three German MS centres.Patient regarding DMT, TSQM-9, SF36, self-reported adherence as well relapses EDSS recorded baseline every 3 6 months for up years.Results: Efficacy highest-ranking baseline.Actual selection corresponded more closely safety than tolerability, or convenience preferences.Participants reported excellent throughout study.DMT persistence was 69.0%, earlier discontinuation injectable vs oral infusion therapies.Breakthrough disease, rather patient-reported outcomes, main driver discontinuation.For all routes administration, global satisfaction increased over time despite lower convenience.Several patterns changing observed. Conclusion:This provides insight into interaction experience.Treatment decisions should be aligned promote continuous adherence.

Language: Английский

Citations

Cloud and IoT based Smart Agent-driven Simulation of Human Gait for Detecting Muscles Disorder DOI

Sina Saadati,

Abdolah Sepahvand,

Mohammadreza Razzazi

et al.

Heliyon, Journal Year: 2025, Volume and Issue: 11(2), P. e42119 - e42119

Published: Jan. 1, 2025

Motion disorders affect a significant portion of the global population. While some symptoms can be managed with medications, these treatments often impact all muscles uniformly, not just affected ones, leading to potential side effects including involuntary movements, confusion, and decreased short-term memory. Currently, there is no dedicated application for differentiating healthy from abnormal ones. Existing analysis applications, designed other purposes, lack essential software engineering features such as user-friendly interface, infrastructure independence, usability learning ability, cloud computing capabilities, AI-based assistance. This research proposes computer-based methodology analyze human motion differentiate between unhealthy muscles. First, an IoT-based approach proposed digitize using smartphones instead hardly accessible wearable sensors markers. The data then simulated neuromusculoskeletal system. An agent-driven modeling method ensures naturalness, accuracy, interpretability simulation, incorporating neuromuscular details Henneman's size principle, action potentials, motor units, biomechanical principles. results are provided medical clinical experts aid in further investigation. Additionally, deep learning-based ensemble framework assist simulation results, offering both accuracy interpretability. A graphical interface enhances application's usability. Being fully cloud-based, infrastructure-independent accessed on smartphones, PCs, devices without installation. strategy only addresses current challenges treating but also paves way simulations by considering scientific computational requirements.

Language: Английский

Citations

Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review DOI

Armin Adibi, Iman Adibi,

Manouchehr Javidan

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2025, Volume and Issue: 31(1)

Published: Jan. 1, 2025

ABSTRACT Background Multiple sclerosis (MS) is an autoimmune disorder affecting the central nervous system, with varying clinical manifestations such as optic neuritis, sensory disturbances, and brainstem syndromes. Disease progression monitored through methods like MRI scans, disability scales, optical coherence tomography (OCT), which can detect retinal thinning, even in absence of neuritis. MS involves neurodegeneration, particularly trans‐synaptic degeneration, extends beyond initial injury site. This review focuses on impact different treatments thickness assessed by OCT. Results Injectable drugs, interferon beta glatiramer acetate (GA), have a relatively modest atrophy. Oral medications Fingolimod, Teriflunomide, Dimethyl fumarate also impacts thickness. Fingolimod has been shown to protect against thinning but may lead macular edema. DMF‐treated patients had less ganglion cell–inner plexiform layer than GA‐treated more compared natalizumab‐treated healthy controls. Teriflunomide's layers remains unexplored human studies. Monoclonal antibodies, including Alemtuzumab, Rituximab, Ocrelizumab, Natalizumab, protective effects Alemtuzumab‐treated showed significantly atrophy interferon‐ patients. Rituximab initially increased rates first months subsequently demonstrated potential neuroprotective effects. Ocrelizumab slowed rate inner nuclear progressive forms disease. Natalizumab considered most effective reducing atrophy, peripapillary nerve fiber layer. Conclusions It's important note that effectiveness these vary depending subtype individual factors. Future research should explore long‐term their correlations overall disease

Language: Английский

Citations

Therapeutic potential of Pranlukast against cuprizone-induced inflammatory demyelination and sensory impairment in mice: comparison with Fingolimod. DOI

Gabriel Natan Pires,

Renata Pereira Laurindo,

Luiza dos Santos Heringer

et al.

NeuroToxicology, Journal Year: 2025, Volume and Issue: 107, P. 37 - 52

Published: Jan. 31, 2025

Language: Английский

Citations